In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand.
Src signalling and transduction are directly involved in cell growth, cell cycle, malignant transformation and cell migration, providing therapeutic opportunities through inhibition of Src. Here we report virtual screening for novel compounds that inhibit the Src-SH3 protein-protein interaction with a proline-rich peptide ligand. Computational docking of the ZINC compound database was performed using GOLD. Top-scoring compounds were assayed using a fluorescence polarization-based assay. A benzoquinoline derivative showed micromolar inhibition of binding between Src-SH3 and the proline-rich peptide. Several analogues were subsequently assayed showing the requirement of a linker between the benzoquinoline and phenyl rings, and electron donating substituents on the phenyl ring.
Atatreh
Noor
N
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PT, UK.
Stojkoski
Cvetan
C
Smith
Phillippa
P
Booker
Grant W
GW
Dive
Caroline
C
Frenkel
A David
AD
Freeman
Sally
S
Bryce
Richard A
RA
D000595:Amino Acid Sequence; D020650:Combinatorial Chemistry Techniques; D018360:Crystallography, X-Ray; D004354:Drug Screening Assays, Antitumor; D008958:Models, Molecular; D011392:Proline / Q000737:chemistry*; D011485:Protein Binding; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000037:antagonists & inhibitors*; D011804:Quinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
D011804:Quinolines; D011392:Proline; D016392:Proto-Oncogene Proteins pp60(c-src)